Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration

Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require f...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaiser, Stephanie M, Arepalli, Sruthi, Ehlers, Justis P
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488047/
https://www.ncbi.nlm.nih.gov/pubmed/34616189
http://dx.doi.org/10.2147/JEP.S259298
_version_ 1784578068205010944
author Kaiser, Stephanie M
Arepalli, Sruthi
Ehlers, Justis P
author_facet Kaiser, Stephanie M
Arepalli, Sruthi
Ehlers, Justis P
author_sort Kaiser, Stephanie M
collection PubMed
description Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended.
format Online
Article
Text
id pubmed-8488047
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-84880472021-10-05 Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration Kaiser, Stephanie M Arepalli, Sruthi Ehlers, Justis P J Exp Pharmacol Review Age-related macular degeneration (AMD) is the most common cause of legal blindness in developed countries. Neovascular (ie, wet) AMD is currently managed with intravitreal therapy. Traditional treatments (ie, bevacizumab, ranibizumab, aflibercept) provide high-efficacy therapy but can also require frequent dosing. Newer and future anti-VEGF therapies aim to decrease injection frequency through eitherlonger half life or port-delivery systems (brolucizumab, conbercept, KSI-301, ranibizumab). This review outlines current anti-VEGF treatments and ways by which their duration might be extended. Dove 2021-09-29 /pmc/articles/PMC8488047/ /pubmed/34616189 http://dx.doi.org/10.2147/JEP.S259298 Text en © 2021 Kaiser et al. https://creativecommons.org/licenses/by-nc/3.0/This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/ (https://creativecommons.org/licenses/by-nc/3.0/) ). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Review
Kaiser, Stephanie M
Arepalli, Sruthi
Ehlers, Justis P
Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title_full Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title_fullStr Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title_full_unstemmed Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title_short Current and Future Anti-VEGF Agents for Neovascular Age-Related Macular Degeneration
title_sort current and future anti-vegf agents for neovascular age-related macular degeneration
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488047/
https://www.ncbi.nlm.nih.gov/pubmed/34616189
http://dx.doi.org/10.2147/JEP.S259298
work_keys_str_mv AT kaiserstephaniem currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration
AT arepallisruthi currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration
AT ehlersjustisp currentandfutureantivegfagentsforneovascularagerelatedmaculardegeneration

Ejemplares similares